ArticleEuropean journal of nuclear medicine and molecular imaging2024
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- CXCR4-targeted [European journal of nuclear medicine and molecular imaging · 2026Trial
- Association of Atherosclerosis [Molecular imaging and biology · 2026Article
- More extensive lesion and intense uptake detected by [⁶⁸Ga]Ga-PentixaFor PET/CT Than [European journal of nuclear medicine and molecular imaging · 2026Article
- Primary extranodal marginal zone lymphoma of gastric mucosa-associated lymphoid tissue in children: a case report and review of the literature.Journal of medical case reports · 2026Review
- Article
- Physiological uptake patterns of gastric lymph node stations onQuantitative imaging in medicine and surgery · 2026Article
- Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Physiological distribution and dosimetry of AlBMC medical imaging · 2026Article
- Complementary roles ofArchive of clinical cases · 2026Article
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin's lymphoma.EJNMMI research · 2025Article
- CXCR4-targeted Imaging in DLBCL: A Prospective Head-to-head Comparison ofIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundIn patients with marginal zone lymphoma (MZL), [
methodsThirty-two untreated MZL patients (nodal, n = 17; extranodal, n = 13; splenic, n = 2) received [
resultsOn a patient-based level, [
conclusionsIn newly diagnosed MZL patients, [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.